Accumulating evidence indicated that the oncogenic effect of UTX loss is mediated mainly through an increase in the EZH2 level in lung cancer [16], and UTX loss sensitizes cells to EZH2 inhibition in multiple myeloma [18]. This evidence concerns the gene EZH2 and plasma cell myeloma.